

Correspondence

Reply

To the Editor:

Incorvaia et al¹ have commented that “studies addressing the synergy of omalizumab in combination with allergen immunotherapy to achieve long-term effectiveness are warranted to prove the rationality of this model.”

We agree with the correspondents that additional studies are needed to clarify the optimal conditions and patient selection for the combination of allergen immunotherapy with omalizumab. As stated in Table I of our article,² there is only moderate-quality data to support the facilitation of subcutaneous immunotherapy to aeroallergens.

*Juan Carlos Cardet, MD, MPH
Thomas B. Casale, MD*

From the Department of Internal Medicine, Division of Allergy and Immunology, Morsani College of Medicine of the University of South Florida, Tampa, Fla. E-mail: tbcasale@health.usf.edu.

Supported by grants K23AI125785 (to J.C.C.) and R01HL116849 (to T.B.C.) and by generous contributions by the Culverhouse Family Fund (to both J.C.C. and T.B.C.). Disclosure of potential conflict of interest: T. B. Casale was involved in several clinical trials using omalizumab, including industry-sponsored trials and reports that his university has received grants and consulting fees from Genentech, and Novartis. J. C. Cardet declares that he has no relevant conflicts of interest.

REFERENCES

1. Incorvaia C, Riario-Sforza GG, Ridolo E. The many abilities of omalizumab and the unbeaten path. *J Allergy Clin Immunol* ■■■;■■■:■■■.
2. Cardet JC, Casale TB. New insights into the utility of Omalizumab. *J Allergy Clin Immunol* 2019;143:923-6.

<https://doi.org/10.1016/j.jaci.2019.03.014>